These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 45368)

  • 1. Drug-induced extrapyramidal side-effects in Egyptian schizophrenic patients.
    Okasha A; El Okbi H; Sadek A; Lotiaf F; Ashour AM
    Egypt J Psychiatry; 1979 Oct; 2(2):191-7. PubMed ID: 45368
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of drugs in schizophrenia. Discussion on assessment of drug-induced extrapyramidal reactions.
    McClelland HA
    Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):401-3. PubMed ID: 9966
    [No Abstract]   [Full Text] [Related]  

  • 3. [Aspects of neuroleptic depot therapy with special consideration of clinical experiences with the preoral depot preparation Penfluridol (R 16 341-Jannsen)].
    Bruck J; Guss H
    Int Pharmacopsychiatry; 1974; 9(3):152-65. PubMed ID: 4154320
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy.
    Lavin MR; Rifkin A
    J Clin Pharmacol; 1991 Aug; 31(8):769-77. PubMed ID: 1679063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sudden dysphagia with uvular enlargement following the initiation of risperidone which responded to benztropine: was this an extrapyramidal side effect?
    Nair S; Saeed O; Shahab H; Sedky K; Garver D; Lippmann S
    Gen Hosp Psychiatry; 2001; 23(4):231-2. PubMed ID: 11569473
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients.
    Elizur A; Segal S; Yeret A; Ben-David M
    Isr Ann Psychiatr Relat Discip; 1979 Dec; 17(4):318-27. PubMed ID: 44877
    [No Abstract]   [Full Text] [Related]  

  • 7. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients.
    Wada Y; Yamaguchi N
    Neuropsychobiology; 1992; 25(3):149-52. PubMed ID: 1357583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
    Sramek JJ; Simpson GM; Morrison RL; Heiser JF
    J Clin Psychiatry; 1986 Jun; 47(6):305-9. PubMed ID: 2872206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biperiden (Akineton): effective prophylactic and therapeutic anti-parkinsonian agent.
    Kline NS; Mason BT; Winick L
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):838-43. PubMed ID: 4155670
    [No Abstract]   [Full Text] [Related]  

  • 10. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
    Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
    Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexetimide: an effective drug for the control of extrapyramidal symptoms induced by pipothiazine palmitate.
    Dom R; Van Lommel R; Baro F
    Acta Psychiatr Scand; 1973; 49(5):563-9. PubMed ID: 4148581
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms.
    Murphy JE; Stewart RB
    Am J Hosp Pharm; 1979 May; 36(5):641-4. PubMed ID: 36755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models.
    Casey DE
    Br J Psychiatry Suppl; 1996 May; (29):32-9. PubMed ID: 8733821
    [No Abstract]   [Full Text] [Related]  

  • 14. [A practical guide for the use of psychopharmacologic agents. II. Antipsychotic and antiparkinson agents].
    Chouinard G
    Union Med Can; 1976 Sep; 105(9):1387-97. PubMed ID: 9720
    [No Abstract]   [Full Text] [Related]  

  • 15. Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics.
    Strejilevich SA; Palatnik A; Avila R; Bustin J; Cassone J; Figueroa S; Gimenez M; de Erausquin GA
    Psychiatry Res; 2005 Feb; 133(2-3):277-80. PubMed ID: 15741003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic drugs--an update.
    Charalampous KD; Keepers GA
    J Okla State Med Assoc; 1978 Jan; 71(1):6-9. PubMed ID: 23420
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
    Cesková E; Svestka J
    Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why do schizophrenic patients refuse to take their drugs?
    Van Putten T
    Arch Gen Psychiatry; 1974 Jul; 31(1):67-72. PubMed ID: 4151750
    [No Abstract]   [Full Text] [Related]  

  • 20. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon.
    Bermanzohn PC; Siris SG
    J Clin Psychiatry; 1994 Nov; 55(11):488-91. PubMed ID: 7989282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.